Trial
NCT06685068
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Genmab
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
GEN1286
Why stopped
Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-08